AIkido Pharma Inc. dina iki nglaporake peningkatan proses manufaktur kanggo obat kanker pankreas, DHA-dFdC, sing dilisensi saka Universitas Texas ing Austin. Perusahaan uga nglaporake penerbitan paten AS tambahan sing nutupi obat kasebut, lan pengajuan aplikasi paten terusan sing dimaksudake kanggo nggedhekake jangkoan paten menyang aspek obat liyane.
Babagan proses manufaktur, Perusahaan nglaporake pangembangan sukses cara anyar kanggo produksi skala lan isolasi senyawa penengah utama ing pabrik DH-dFdC. Perusahaan saiki wis ngetrapake kontrak luwih lanjut karo organisasi manufaktur kontrak, Parimer Scientific, kanggo nggunakake proses anyar kanggo ngasilake pirang-pirang ewu miligram obat kanggo digunakake ing pangembangan formulasi lan studi stabilitas. Perusahaan uga nglapurake yen Kantor Paten AS bubar ngetokake Paten AS anyar No. 11,219,633, sing nyedhiyakake perlindungan properti intelektual tambahan kanggo senyawa obat kasebut. Istilah paten kasebut bakal terus nganti Mei 2035 kanthi mbayar biaya pangopènan sing dibutuhake. Sadurunge nerbitake paten, Perusahaan menehi wewenang pengajuan pas wektune saka aplikasi paten terusan, US Serial No.
Anthony Hayes, CEO AIkido, ujar, "Proses anyar iki minangka langkah maju sing signifikan ing pangembangan obat kanker pankreas lan kudu ngidini produksi obat kasebut ing skala komersial kanthi biaya sing luwih murah. Aku uga seneng yen kita bisa terus nglaporake ekspansi properti paten.
Richard T. Pace, Pemilik lan Ilmuwan Utama Parimer Scientific, nyatakake, "Cara manufaktur sing mentas dikembangake minangka langkah gedhe kanggo teknologi inovatif iki. Aku yakin bakal nyuda biaya saben unit lan ing wektu sing padha nambah volume produksi batch.
APA sing kudu dijupuk saka ARTIKEL INI:
- With respect to manufacturing process, the Company reported the successful development of a new means for the scaled production and isolation of the key intermediate compound in the manufacture of DH-dFdC.
- Anthony Hayes, CEO of AIkido, stated, “This new process significant step forward in the development of our pancreatic cancer drug and should permit production of the drug on a commercial scale at a lower cost.
- The Company has now executed a further contract with its contract manufacturing organization, Parimer Scientific, to employ the new process to produce several thousand milligrams of the drug for use in formulation development and stability studies.
